R&D Europe’s growing vector-borne disease threat: Are we keeping... In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.
R&D Mosquitoes, malaria, and UK R&D viral disease vaccine invest... The UK must sustain investment in malaria R&D as it faces a “perfect storm” of challenges, including mosquito resistance to existing tools.
News Viral disease-carrying Aedes mosquito 'breeding in London' Invasive Aedes mosquitoes and their larvae have been found in London, but the UKHSA says the risk to the public from diseases they can carry is low.
News France probes side effects with Valneva's chikungunya jab France's national public health agency has halted dosing of Valneva's chikungunya vaccine in older people while it investigates a safety signal.
News Bavarian Nordic chikungunya vaccine gets FDA okay There are now two vaccines to protect against chikungunya approved for use in the US, after Bavarian Nordic gets the green light for Vimkunya.
News CHMP backs Bavarian Nordic's chikungunya jab Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.